Sign in →

Test Code COMCP Hereditary Common Cancer Panel, Varies


Ordering Guidance


Customization of this panel and single gene analysis for any gene present on this panel are available. For more information see CGPH / Custom Gene Panel, Hereditary, Next-Generation Sequencing, Varies.

 

Targeted testing for familial variants (also called site-specific or known mutations testing) is available for the genes on this panel. For more information see FMTT / Familial Variant, Targeted Testing, Varies. To obtain more information about this testing option, call 800-533-1710.

 

Testing minors for adult-onset predisposition syndromes is discouraged by the American Academy of Pediatrics, the American College of Medical Genetics and Genomics, and the National Society of Genetic Counselors.



Shipping Instructions


Specimen preferred to arrive within 96 hours of collection.



Specimen Required


Patient Preparation: A previous bone marrow transplant from an allogenic donor will interfere with testing. Call 800-533-1710 for instructions for testing patients who have received a bone marrow transplant.

Specimen Type: Whole blood

Container/Tube:

Preferred: Lavender top (EDTA) or yellow top (ACD)

Acceptable: Any anticoagulant

Specimen Volume: 3 mL

Collection Instructions:

1. Invert several times to mix blood.

2. Send whole blood specimen in original tube. Do not aliquot.

Specimen Stability Information: Ambient (preferred) 4 days/Refrigerated


Forms

1. New York Clients-Informed consent is required. Document on the request form or electronic order that a copy is on file.

-Informed Consent for Genetic Testing (T576)

-Informed Consent for Genetic Testing (Spanish) (T826)

2. Molecular Genetics: Inherited Cancer Syndromes Patient Information Sheet (T519)

3. If not ordering electronically, complete, print, and send a Oncology Test Request (T729) with the specimen.

Secondary ID

614319

Useful For

Evaluating hereditary cancer for patients with a personal or family history suggestive of a hereditary cancer syndrome

 

Establishing a diagnosis of a hereditary cancer syndrome allowing for targeted cancer surveillance based on associated risks

 

Identifying genetic variants associated with increased risk for cancer, allowing for predictive testing, and appropriate screening of at-risk family members

 

Therapeutic eligibility with poly adenosine diphosphate-ribose polymerase (PARP) inhibitors based on certain gene alterations (eg, BRCA1, BRCA2) in selected tumor types

Genetics Test Information

This test utilizes next-generation sequencing to detect single nucleotide and copy number variants in 36 genes associated with hereditary cancer syndromes: APC (including promoters 1A and 1B), ATM, AXIN2, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, DICER1, EPCAM (copy number variants only), GREM1 (upstream enhancer region duplication only), HOXB13, MEN1, MLH1, MSH2, MSH3, MSH6, MUTYH, NBN, NF1, NTHL1, PALB2, PMS2, POLD1, POLE, PTEN (including promoter), RAD51C, RAD51D, RET, SMAD4, STK11, TP53. For more information, see Method Description and Targeted Genes and Methodology Details for Hereditary Common Cancer Panel.

 

Identification of a disease-causing variant may assist with diagnosis, prognosis, clinical management, familial screening, and genetic counseling for hereditary cancer syndromes.

Disease States

  • Breast cancer

Method Name

Sequence Capture and Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Sanger Sequencing and/or Multiplex Ligation-Dependent Probe Amplification (MLPA)

Reporting Name

Hereditary Common Cancer Panel

Specimen Type

Varies

Specimen Minimum Volume

1 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Varies Varies

Reject Due To

All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.

Clinical Information

Hereditary cancer syndromes account for approximately 5% to 10% of cancer cases.(1,2) Determining if there is a genetic risk factor contributing to cancer in an individual or family can be useful for tailoring surveillance plans, consideration of prophylactic risk reducing interventions, consideration of targeted treatments, and determining risk for family members.(3-9)

 

This panel evaluates 36 genes known to be associated with an increased risk of polyposis and several common cancers, including breast, colon, gastric, ovarian, pancreatic, prostate, skin, thyroid, and endometrial cancers. The risk for developing cancer, as well as other features associated with these syndromes, varies. Many of the genes on this panel have established cancer risk and National Comprehensive Cancer Network or expert group guidelines and recommendations for management.(3-8)

 

Indications for testing include but are not limited to:

-Individuals with multiple primary cancers

-Individuals with cancer diagnosed at young ages

-Individuals with a family history of multiple relatives with cancer

-Individuals whose family history of cancer may seem to overlap with more than one hereditary cancer syndrome

Reference Values

An interpretive report will be provided.

Interpretation

All detected variants are evaluated according to American College of Medical Genetics and Genomics recommendations.(1) Variants are classified based on known, predicted, or possible pathogenicity and reported with interpretive comments detailing their potential or known significance.

Day(s) Performed

Varies

Report Available

21 to 28 days

Specimen Retention Time

Whole blood: 2 weeks (if available); Extracted DNA: 3 months

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

81201
81408 x2
81162
81406 x4
81404
81403
81405 x2
81292
81295
81298
81307
81317
81319
81321
81351
81479
81479 (if appropriate for government payers)

LOINC Code Information

Test ID Test Order Name Order LOINC Value
COMCP Hereditary Common Cancer Panel 97656-3

 

Result ID Test Result Name Result LOINC Value
614683 Test Description 62364-5
614684 Specimen 31208-2
614685 Source 31208-2
614686 Result Summary 50397-9
614687 Result 82939-0
614688 Interpretation 69047-9
614689 Resources 99622-3
614690 Additional Information 48767-8
614691 Method 85069-3
614692 Genes Analyzed 48018-6
614693 Disclaimer 62364-5
614694 Released By 18771-6

Testing Algorithm

For more information see Lynch Syndrome Testing Algorithm.